FBXW7-DISC1 complex linked to schizophrenia

In a paper, researchers showed that F-box and WD repeat domain containing 7 (FBXW7; FBW7) controls levels of a scaffold protein, disrupted in schizophrenia 1 (DISC1), which is deficient in hereditary schizophrenia. The research suggests that targeting the FBXW7-DISC1 complex could be used to treat neuropsychiatric diseases such as schizophrenia and bipolar disorder.

The paper's authors included researchers from the University of Glasgow, Pfizer Inc. (NYSE:PFE), University of Connecticut, AstraZeneca plc (LSE:AZN; NYSE:AZN), Heriot-Watt University and King's College London. The University of Glasgow said Molecular Psychiatry is publishing the paper. Pfizer funded the study...